Castle Biosciences Inc (CSTL)vsDanaher Corporation (DHR)
CSTL
Castle Biosciences Inc
$19.83
+3.07%
HEALTHCARE · Cap: $583.55M
DHR
Danaher Corporation
$171.16
-2.56%
HEALTHCARE · Cap: $124.33B
Smart Verdict
WallStSmart Research — data-driven comparison
Danaher Corporation generates 7098% more annual revenue ($24.78B vs $344.23M). DHR leads profitability with a 14.9% profit margin vs -7.0%. DHR earns a higher WallStSmart Score of 58/100 (C).
CSTL
Avoid33
out of 100
Grade: F
DHR
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+65.9%
Fair Value
$94.72
Current Price
$19.83
$74.89 discount
Margin of Safety
-24.9%
Fair Value
$137.02
Current Price
$171.16
$34.14 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 22.9%
Generating 1.1B in free cash flow
Areas to Watch
0.8% revenue growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -5.2% — below average capital efficiency
Premium valuation, high expectations priced in
3.7% revenue growth
ROE of 7.1% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CSTL
The strongest argument for CSTL centers on Price/Book, Debt/Equity, Altman Z-Score.
Bull Case : DHR
The strongest argument for DHR centers on Market Cap, Price/Book, Operating Margin. PEG of 1.11 suggests the stock is reasonably priced for its growth.
Bear Case : CSTL
The primary concerns for CSTL are Revenue Growth, Market Cap, Piotroski F-Score.
Bear Case : DHR
The primary concerns for DHR are P/E Ratio, Revenue Growth, Return on Equity.
Key Dynamics to Monitor
CSTL profiles as a turnaround stock while DHR is a value play — different risk/reward profiles.
CSTL carries more volatility with a beta of 1.11 — expect wider price swings.
DHR is growing revenue faster at 3.7% — sustainability is the question.
DHR generates stronger free cash flow (1.1B), providing more financial flexibility.
Bottom Line
DHR scores higher overall (58/100 vs 33/100). CSTL offers better value entry with a 65.9% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Castle Biosciences Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Castle Biosciences Inc. is a cutting-edge diagnostics company dedicated to transforming patient care through its innovative gene-expression profiling tests, particularly in the realm of skin cancer. Its flagship product, DecisionDx®-Melanoma, is instrumental in the management of melanoma, providing critical insights into patient risk stratification and treatment decision-making. With a robust commitment to precision medicine, Castle is actively expanding its portfolio of assays to address unmet clinical needs. Bolstered by a strong research and development focus and an ambitious pipeline, the company is strategically positioned for sustainable growth while enhancing clinical outcomes and delivering significant value to its shareholders in the evolving oncology marketplace.
Visit Website →Danaher Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?